ClinicalTrials.gg
CompletedNCT00348192Updated Jun 2, 2009

SB-742457 And Donepezil In Alzheimer's Disease

A Phase 2 interventional study of SB-742457 and donepezil in Alzheimer's Disease, sponsored by GlaxoSmithKline. Completed at 26 sites in 8 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2009-06-02.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
12th of 58
200 · median 79
Started
2006
with 3 others
Phase 2
4 of 60
none open now
Registered
10th of 60
by date

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 12th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2006, is one of 4 in phase 2, and was the 10th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's Disease.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • cognition global functioning
  • symptomatic
  • SB-742457
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of probable mild-to-moderate Alzheimer's Disease as determined by the NINCDS-ADRDA and criteria with an score of 12-24.
  • Subjects and their caregivers must provide prior to study entry.
  • Adequate blood pressure and laboratory values.

Exclusion criteria

Exclusion criteria:

  • Females of .
  • Have other causes of dementia such as vascular damage, depression, bipolar affective disorder, schizophrenia, syphilis, vitamin B12 deficiency or thyroid deficiency.
  • Subjects taking medication for Alzheimers disease or centrally acting agents which might impact study outcomes.
  • Subjects taking agents for which there is a theoretical risk of interaction with SB-742457 or donepezil.
  • Subjects with conditions which might be exacerbated by exposure to donepezil.
  • Subjects with known to sunlight or seizures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
200 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in cognition and function after 24 weeks.

Secondary outcomes

  1. Change in behavioral symptoms, activities of daily living and caregiver burden after 24 weeks Changes in all symptoms at 8 and 12 weeks Safety and tolerability PK (pharmacokinetic) profiling. Efficacy related to ApoE and HTR6 status

07

Study locations

26 sites
  • GSK Investigational Site
    Hall in Tirol, A-6060, Austria
  • GSK Investigational Site
    Vienna, A-1130, Austria
  • GSK Investigational Site
    Vienna, A-1220, Austria
  • GSK Investigational Site
    Sofia, 1113, Bulgaria
  • GSK Investigational Site
    Sofia, 1431, Bulgaria
  • GSK Investigational Site
    Varna, 9010, Bulgaria
  • GSK Investigational Site
    Providencia / Santiago, Región Metro De Santiago 7500710, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7560356, Chile
  • GSK Investigational Site
    Valparaiso, Valparaíso 2352499, Chile
  • GSK Investigational Site
    Tallinn, 10617, Estonia
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Ostfildern, Baden-Wuerttemberg 73760, Germany
  • GSK Investigational Site
    Huettenberg, Hessen 35625, Germany
  • GSK Investigational Site
    Achim, Niedersachsen 28832, Germany
  • GSK Investigational Site
    Baesweiler, Nordrhein-Westfalen 52499, Germany
  • GSK Investigational Site
    Hattingen, Nordrhein-Westfalen 45525, Germany
  • GSK Investigational Site
    Moscow, 115552, Russian Federation
  • GSK Investigational Site
    Moscow, 117049, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197022, Russian Federation
  • GSK Investigational Site
    St.-Petersburg, 198103, Russian Federation
  • GSK Investigational Site
    Bratislava, 811 01, Slovakia
  • GSK Investigational Site
    Bratislava, 826 06, Slovakia
  • GSK Investigational Site
    Bratislava, 831 03, Slovakia
  • GSK Investigational Site
    Bradford, BD7 1HR, United Kingdom
  • GSK Investigational Site
    Swindon, SN1 4HZ, United Kingdom
  • GSK Investigational Site
    West of Scotland Science Park, Glasgow, G20 0XA, United Kingdom
08

References and documents

Publications

  • Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011 May;26(5):536-44. doi: 10.1002/gps.2562. Epub 2010 Sep 24. PubMed 20872778 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00348192
Lead sponsor
GlaxoSmithKline
First posted
Jul 4, 2006
Start date
May 2006
Last update
Jun 2, 2009

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Intepirdine · Donepezil

Start the discussion